Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Improving Lives Together

Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make the difference in their everyday lives.

Specialty pharmaceutical company

Providing solutions to unmet medical needs.

Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.

Find out more

Our Products

Feraccru® / Accrufer® : A treatment for iron deficiency with or without anaemia

Our lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s.

In Europe it is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA – where the product also benefits from NCE exclusivity until 2024 – it will be marketed as Accrufer®.

We also have an exclusive licence agreement with ASK Pharm, who will lead development and commercialisation in China.

Find out more

The content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.

Shield Therapeutics CEO says reanalysis of key study has shown Feraccru to be ‘credible alternative’

Aug 2020 - 08:52
View all Investors Audio & Video